Subcutaneous implant with etonogestrel (Implanon®) for catamenial exacerbations in a patient with cystic fibrosis: a case report

Adelaida Lamas1,2*, Luis Máiz3, Marta Ruiz de Valbuena1, José Manuel González-Casbas4 and Lucrecia Suárez5

Abstract

**Background:** Cystic Fibrosis (CF) is a genetic disease with equal prevalence across sexes. However, women present worse lung function with faster function decline, earlier onset of bacterial colonization, more frequent pulmonary exacerbations (PE), greater bronchial hyper-responsiveness, and higher mortality rates after puberty than men. The etiology of this gender disparity remains elusive but female hormones have been implicated in several studies.

**Case presentation:** A 20-year-old female with CF with severe recurrent PE, always related to the menstrual cycle since menarche, combined with lung function decline requiring multiple courses of intravenous antibiotics. We report the cessation of PE and recovery of pulmonary function following the insertion of a subcutaneous implant with 68 mg of etonogestrel (Implanon®, Organon Española S.A. Laboratories, Madrid, Spain).

**Conclusion:** Our case report supports the key role of female hormones in the development of PE and in the decline of lung function in a woman with CF. When appropriate, hormonal manipulation through contraceptive methods should be considered as potential treatment.

**Keywords:** Cystic fibrosis, Pulmonary exacerbations, Female hormones, Oral contraceptives, Hormonal contraception
our favorable experience using a subcutaneous implant with etonogestrel (Implanon®) to reduce PE frequency and improve LF in a woman with CF.

Case presentation
The patient was a 20-year-old female with CF, genotype R334W/Q890X and pancreatic sufficiency, diagnosed as a 3 month-old due to respiratory symptoms. Since diagnosis, the patient had had several PE caused by β-lactamase producer methicillin-susceptible *Staphylococcus aureus* (*S. aureus*). At the age of 5, she experienced the first of many acute pancreatitis (AP) episodes secondary to several oral medications, including antibiotics. These episodes, associated with continuous PE, led to the insertion of a port-a-cath. Non mucoid *P. aeruginosa* isolations grew in five samples from April 2000 to September 2009 and three samples of *Stenotrophomonas maltophilia* were also collected, once in 2005 and twice in 2010. The patient was treated with intermittent aerosolized antibiotics (tobramycin and colistin) following the Spanish Protocol for eradication of *P. aeruginosa*, and was on azithromycin (500 mg, three times a week) from February 2007 to July 2009 [20]. Sputa acid-fast bacilli smears and cultures for mycobacterium isolates were consistently negative.

From the onset of menarche at the age of 14, PE had followed the same pattern. Four days before the menstrual period, she would start experiencing increased cough and purulent sputum production, develop daily fever (>38°C), exertional dyspnea, and anorexia. In February 2007, due to frequent PE and rapid LF decline, she was started on aerosolized ampicillin (Gobemicina®, Normon Laboratories, Madrid, Spain) every 12 hours. As previously reported [21], the response to this treatment was excellent for a year. On February 2008 she again suffered severe and frequent PE, even while on aerosolized ampicillin, and always related to menstrual cycle as described above. We then introduced an OCP with 3 mg of drospirenone and 30 mcg of etinilestradiol (Yasmin Diario®, Schering España S.A. Laboratories, Madrid, Spain) with initial good response and no PE for 7 months. On September 2008, the same pattern of PE described above re-started requiring five courses of intravenous (IV) antibiotics. From March through May of 2009, the patient was administered an OCP with 2.0 mg of ciproterone acetate and 0.035 mg of etinilestradiol (Diane 35®, Schering España S.A. Laboratories, Madrid, Spain). The lack of response called for four courses of IV antibiotics. In total, from February 2008 until May 2009 she required 20 weeks of IV antibiotics (ceftazidime, linezolid, imipenem, trimethoprim-sulfamethoxazole, or a combination of these; Figure 1). We observed a dramatic loss of LF as follows (Figure 1): forced expired volume in 1 second (FEV₁) decreased from 2.33 L to 1.31 L (77% to 42% of FEV₁ predicted) and forced vital capacity (FVC) decreased from 2.71 L to 1.49 L (79% to 42% of FVC predicted). In addition, she had five AP episodes. In May 2009, after discussing the case with the Department of Gynaecology, a subcutaneous implant with 68 mg of etonogestrel (Implanon®, Organon Española S.A. Laboratories, Madrid, Spain) was inserted in the inner side of her left arm. Estradiol levels had not been measured in this patient. Since then the patient had no PE episodes for two years, she did not require any oral or IV antibiotics, and her LF stabilized around 1.61 L for FEV₁ (48% of FEV₁ predicted) and 2.16 for FVC (57% of FVC predicted). In addition, the treatment resulted in a weight gain of 3 Kg (from 50 kg [10th percentile] to 53 kg [25th-50th percentile]). Further, no side effects were observed during this period, the pattern of *S. aureus* colonization did not change, and no selection of resistant microorganisms appeared except a unique isolation of non-mucoid *P. aeruginosa*, previously reported, four months after the insertion of the subcutaneous implant. From September 2009 through September 2010, we introduced aerosolized tobramycin (TOBI®, Novartis Laboratories) in on-off cycles following the Spanish Protocol for eradication of *P. aeruginosa*. In July 2011, the patient had a severe PE episode requiring treatment with IV antibiotic. At this point, the subcutaneous implant was replaced for another one. The patient has been PE episode-free since December 2012.

Discussion
CF is a genetic disease with the same prevalence in both men and women. However, women experience worse LF, early onset bacterial colonisations, and lower survival expectancy than men [1-3,22]. E levels are involved in mucus secretion, lung development, expression of inflammatory factors, risk for *P. aeruginosa* colonization and its further conversion to mucoid phenotype, modification of the activity of the CFTR, and alterations of MCC and ion transport in the ASL [10,15,19,23]. Additionally, P decreases cilia beat frequency in airway epithelial cells [18]. These effects have a negative impact on the MCC of the ASL which may explain, to an important extent, the lower survival in women with CF compared to their male counterparts.

All these mechanisms could have influenced the presentation of PE in our patient during the luteal phase when E and P levels are high. The OCP administered (Yasmin Diario® o Diane 35 Diario®) has a negative feedback mechanism on hypophysis hormones lowering endogenous E’s levels throughout the menstrual cycle, including the pre-ovulation peak. The subcutaneous implant of etonogestrel (Implanon®, Organon Española S.A. Laboratories, Madrid, Spain) has a slow and sustained release of a P derivate which inhibits endogenous progestosterone levels throughout the menstrual cycle, including the luteal phase.
Based on a careful study of this patient’s clinical history we speculate that both the year-long effectiveness of the aerosolized ampicillin treatment and the 7-month effectiveness of the treatment with the first OCP (Yasmin Diario®) may be explained by the patient’s young age. The first two years after the onset of menarche are characterized by anovulatory cycles which cause irregular E and P patterns during the menstrual cycle. After these two years, the patient probably started experiencing regular ovulatory cycles which would have normalized her E and P levels across the normal menstrual cycle. The OCP prescribed (Yasmin Diario® and Diane 35 Diario®) only contain E, thus, they could not be effective in this particular case because our patient had the PE always during the luteal phase, rather than the preovulatory, or immediately before the menstrual phase of the cycle when the E are high. We think the effectiveness of the implant, inserted around two years and a half after menarche, was secondary to the reduction of E and P levels caused by the administration of exogenous P throughout the entire menstrual cycle, including the luteal phase, while withholding administration of exogenous E.

The efficacy of ovulatory inhibition with this type of implant varies from woman to woman across time, diminishing by 10% to up to 50% between year 2 and 5 after insertion. In our case, a substantial loss of efficacy could explain the patient’s new acute PE episode after the first two years post-insertion and the disappearance of clinical symptoms again after the insertion of a new implant.

The genotype of this patient (R334W, class IV mutation, and Q890X, class I mutation) is uncommon and, in this case, associated with a severe expression of the disease with pancreatic sufficiency, numerous episodes of acute pancreatitis, and severe pulmonary disease with frequent PE. Sutton et al. [4] analyzed the United States CF Foundation Patient Registry for a retrospective study of LF decline and rate of PE changes in CF before and after puberty. They concluded that whereas males had lower rate of PE than females, there was no association between annual frequency of PE and race, pancreatic insufficiency, or genotype. Further research is necessary to shed light on the relationship between CF genotype and the effect of female hormones on morbidity/mortality in women.

The effect of female hormones on women with CF is a complex issue given that women have different PE recurrence patterns according to the different phases of the menstrual cycle. Thus, studying the history of PE pattern is essential in order to prescribe one contraceptive method over another (with exogenous E, P, or a combination of both) according to the expression of clinical symptoms of each patient.

**Conclusion**
Pulmonary epithelium is a target for female hormones, including E and P. Their effects on lung function, inflammation, and immune responses may impair MCC and are likely to partially explain the increase in PE frequency observed in women with CF. The case presented here underlines the likely contribution of female hormones to the sex differential in morbidity/mortality in patients with CF. This case supports hormonal manipulation as a potential highly effective therapy for women with CF.
Consent
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
CF: Cystic fibrosis; LF: Lung function; PE: Pulmonary exacerbations; E: Estrogens; P. aeruginosa: Pseudomonas aeruginosa; ASL: Airway surface liquid; CFT: Cystic fibrosis transmembrane conductance regulator; P: Progestrone; OCP: Oral contraceptive pill; AP: Acute pancreatitis; S: aureus: Staphylococcus aureus; FEV1 : Forced expired volume in 1 second; FVC: Forced vital capacity.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
AL drafted the manuscript with LM and LS supervision. MR-V and JMG-C cared for the patient together with the medical team of the CF Unit at Ramón y Cajal University Hospital. All the authors read and approved the final manuscript.

Acknowledgements
We appreciate the collaboration of the patient during all the treatment process and the elaboration of this manuscript.

Funding
The case report was written based on clinical observations without any funding.

Author details
1Department of Paediatric Pulmonology and Cystic Fibrosis Unit, Ramón y Cajal University Hospital, Carretera de Colmenar Km. 9.1, 28034 Madrid, Spain.
2Instituto Ramón y Cajal de Investigación Sanitaria (IRYCS), Madrid, Spain.
3Department of Paediatric Pulmonology and Cystic Fibrosis Unit, Ramón y Cajal University Hospital, Madrid, Spain.
4Department of Gynaecology, Ramón y Cajal University Hospital, Madrid, Spain.
5Department of Paediatric Gastroenterology and Cystic Fibrosis Unit, Ramón y Cajal University Hospital, Madrid, Spain.

Received: 10 April 2014 Accepted: 10 October 2014

References
1. Rosenfield M, Davis R, FitzSimmons S, Pepe M, Ramsey R: Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997, 145(6):794–803.
2. Olesen HV, Pressler T, Hjelte L, Mared L, Lindblad A, Knudsen PK, Laerum BN, Johannessen M: Gender differences in the Scandinavian cystic fibrosis population. Pediatr Pulmonol 2010, 45(10):959–965.
3. Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboza CM, St Clair CG, Young RL, Nichols DP, Janssen JS, Hught GA, Iseman MD, Daley CL, Taylor-Cousar JL, Accurso FJ, Saavedra MT, Sontag MK: Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2010, 182(5):614–626.
4. Sutton S, Rosenbluth D, Raghavan D, Zheng J, Jain R: Effects of puberty on cystic fibrosis related pulmonary exacerbations in women versus men. Pediatr Pulmonol 2014, 49(1):28–35.
5. Demko CA, Byard PJ, Davis PG: Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995, 48(9):1041–1049.
6. Miller CE, Billings J, Moran A: Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005, 28(9):2141–2144.
7. Chotirmall SH, Greene CM, Oglesby IK, Thomas W, O’Neill SJ, Harvey BJ, McElvaney NG: 17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leukoprotease inhibitor. Am J Respir Crit Care Med 2010, 182(1):62–72.
8. Chotirmall SH, Smith SG, Gunaratnam C, Cosgrove S, Dimitrov BD, O’Neill SJ, Harvey BJ, Greene CM, McElvaney NG: Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. Am Eng J Med 2012, 366(21):1978–1986.
9. Massaro D, Massaro GD: Estrogen receptor regulation of pulmonary alveolar dimensions: alveolar sexual dimorphism in mice. Am J Physiol Lung Cell Mol Physiol 2006, 290(5):L866–L870.
10. Zeitlin PL: Cystic fibrosis and estrogens: a perfect storm. J Clin Invest 2008, 118(12):3841–3844.
11. Binns BE, Chotirmall V, Ray JM, Pan JH, Brody SL: Estrogen regulation of cilia beat frequency in airway epithelium. Am J Physiol Lung Cell Mol Physiol 2013, 305(11):L878–L889.
12. Banerjee M, Mitzielfelt JD, Yu L, Yue Q, Duke BJ, Harell CS, Neigh GN, Eaton DC: Estroglol stimulates epithelial sodium channels in rats with acute pulmonary edema. J J Physiol 2003, 549:1183–1192.
13. Sweezy N, Tchepichev S, Gagnon S, Fertuck K, O’Brodingue H: Female gender hormones regulate mRNA levels and function of the rat lung epithelial Na channel. Am J Physiol 1998, 274(2 Pt 1):C379–C386.
14. Noack M, A. M. S. A. N. A., G., C. R. P: Cystic fibrosis. J Lancet 2011, 30(1):78–93.
15. Greenlee MM, Mitzielfelt JD, Yu L, Yue Q, Duke BJ, Harell CS, Neigh GN, Eaton DC: Estroglol stimulates epithelial sodium channels in rats with acute pulmonary edema. J J Physiol 2003, 549:1183–1192.
16. Saint-Criq V, Harvey BJ: Cystic fibrosis related pulmonary exacerbations in women versus men. Pediatr Pulmonol 2009, 44(5):512–515.
17. Chotirmall SH, Greene CM, McElvaney NG: Immune, inflammatory and infectious consequences of estrogen in women with cystic fibrosis. Expert Rev Respir Med 2012, 6(6):573–575.